首页> 外文OA文献 >A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer

【2h】

A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer

机译：一种多中心期II研究，评估日本患者的曲折朱努沙蛋白的疗效，安全性和药代动力学在日本患者中严重预处理HER2阳性局部复发或转移性乳腺癌的疗效，安全性和药代动力学

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Masahiro Kashiwaba; Yoshinori Ito; Shintaro Takao; Hiroyoshi Doihara; Yoshiaki Rai; Kazumitsu Kanatani; Shigemitsu Takashima; Norikazu Masuda;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer [J] . Kashiwaba Masahiro, Ito Yoshinori, Takao Shintaro, Japanese journal of clinical oncology. . 2016,第5期

机译：一项多中心II期研究，评估曲妥珠单抗Emtansine对日本患者进行了严重预处理，HER2阳性是局部复发或转移性乳腺癌的疗效，安全性和药代动力学
2. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer [J] . Lu Dan, Li Chunze, Riggs Matthew, Cancer chemotherapy and pharmacology. . 2019,第1期

机译：Trastuzumab Emtansine（T-DM1）的药代动力学作为单一的药剂，或者与患有复发或局部晚期转移性乳腺癌的HER2阳性乳腺癌患者中的Pertuzumab
3. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer [J] . Yamamoto Harukaze, Ando Masashi, Aogi Kenjiro, Japanese journal of clinical oncology. . 2015,第1期

机译：曲妥珠单抗艾坦在日本HER2阳性转移性乳腺癌患者中的I期和药代动力学研究
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer [O] . Edith A Perez, Sara A Hurvitz, Lukas C Amler, 2014

机译：TDM4450g中一线曲妥珠单抗艾坦相比曲妥珠单抗加多西他赛的疗效与HER2表达之间的关系：一项先前未经治疗的HER2阳性转移性乳腺癌患者的II期随机研究
6. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer [O] . H. Yamamoto, M. Ando, K. Aogi, 2014

机译：曲妥珠单抗在日本患者患者2阳性转移性乳腺癌患者中的I相和药代动力学研究

A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅